Table 1 Clinical features of the patients enrolled in the study
From: A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy
Patient | Gender | Severity of reaction Pre VIT (according to Müller) | Age (years) | VIT duration (months) | Follow-up duration (months) | Total VIT dose (SQ-U ×106) | Total VIT dose (mg) | VIT supplier |
|---|---|---|---|---|---|---|---|---|
N.G. | M | IV | 60 | 61 | 53 | 4.51 | Â | Alk |
T.G. | M | IV | 33 | 58 | 182 | Â | 5.9 | DHS |
P.G. | M | IV | 49 | 59 | 122 | Â | 4.7 | DHS |
C.G. | F | III | 21 | 60 | 184 | Â | 5.1 | DHS |
C.G. | M | III | 45 | 59 | 36 | Â | 5.7 | DHS |
C.G. | M | III | 35 | 60 | 199 | Â | 6.5 | DHS |
D.F.T. | M | IV | 51 | 58 | 103 | 1.82 | Â | Alk |
R.F. | M | IV | 44 | 59 | 151 | 2.05 | Â | Alk |
G.G. | F | III | 39 | 73 | 41 | 4.41 | Â | Alk |
C.M. | F | IV | 37 | 61 | 38 | 2.18 | Â | Alk |
D.M.S | M | III | 54 | 61 | 36 | 4.44 | Â | Alk |
I.N. | M | IV | 54 | 63 | 36 | 2.36 | Â | Alk |
A.A. | M | III | 13 | 63 | 62 | 2.11 | Â | Alk |
C.M. | M | IV | 39 | 64 | 43 | 2.19 | Â | Alk |
D.F. | M | IV | 59 | 64 | 66 | Â | 5.8 | DHS |
T.A. | M | IV | 49 | 62 | 28 | Â | 5.7 | DHS |
V.V. | M | IV | 50 | 59 | 51 | Â | 5.6 | DHS |
T.A. | M | III | 46 | 60 | 44 | 2.57 | Â | Alk |
S.S. | F | III | 29 | 50 | 36 | 3.85 | Â | Alk |
M.S. | M | III | 52 | 64 | 56 | 1.71 | Â | Alk |
M.A. | F | III | 33 | 64 | 27 | 2.28 | Â | Alk |
V.R. | M | IV | 52 | 62 | 37 | Â | 6.5 | DHS |
M.F. | M | IV | 40 | 64 | 31 | Â | 5.7 | DHS |
Mean | Â | Â | 42.78 | 61.22 | 72.26 | 5.73 | 2.80 | Â |
SD | Â | Â | 11.81 | 4.02 | 55.37 | 0.54 | 1.07 | Â |